WSO Russian Language - 26

32.

33.

34.

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.

45.

46.

International Journal of Stroke, 10(1)
using a Delphi consensus process. Dev Med Child Neurol
2017; 59: 713-718.
Edwards HB, Mallick AA and O'Callaghan FJK.
Immunotherapy for arterial ischaemic stroke in childhood:
a systematic review. Arch Dis Child 2017; 102: 410-415.
Steinlin M, Bigi S, Stojanovski B, et al. Focal cerebral
arteriopathy: do steroids improve outcome? Stroke 2017;
48: 2375-2382.
Elbers J, Armstrong D, Yau I and Benseler S. Vascular
imaging outcomes of childhood primary angiitis of the
central nervous system. Pediatr Neurol 2016; 63: 53-59.
Berger TM, Caduff JH and Gebbers JO. Fatal
varicellazoster virus antigen-positive giant cell arteritis of
the central nervous system. Pediatr Infect Dis J 2000; 19:
653-656.
Hayman M, Hendson G, Poskitt KJ and Connolly MB.
Postvaricella angiopathy: report of a case with pathologic
correlation. Pediatr Neurol 2001; 24: 387-389.
Gilden D, Cohrs RJ, Mahalingam R and Nagel MA.
Varicella zoster virus vasculopathies: diverse clinical
manifestations, laboratory features, pathogenesis, and
treatment. Lancet Neurol 2009; 8: 731-740.
Munot P, Crow YJ and Ganesan V. Paediatric stroke:
genetic insights into disease mechanisms and treatment
targets. Lancet Neurol 2011; 10: 264-274.
Milewicz DM, Kwartler CS, Papke CL, Regalado ES, Cao
J and Reid AJ. Genetic variants promoting smooth muscle
cell proliferation can result in diffuse and diverse vascular
diseases: evidence for a hyperplastic vasculomyopathy.
Genet Med 2010; 12: 196-203.
Rutledge WC, Choudhri O, Walcott BP, et al. Indirect and
direct revascularization of ACTA2 cerebral arteriopathy:
feasibility of the superficial temporal artery to anterior
cerebral artery bypass with posterior auricular artery
interposition graft: case report. J Neurosurg Pediatr 2016;
18: 339-343.
Al-Yassin A, Saunders DE, Mackay MT and Ganesan
V. Early-onset bilateral cerebral arteriopathies: cohort
study of phenotype and disease course. Neurology 2015;
85: 1146-1153.
Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke
and vasculopathy associated with mutations in ADA2. N
Engl J Med 2014; 370: 911-920.
Sahin S, Adrovic A, Barut K, et al. Clinical, imaging and
genotypical features of three deceased and five surviving
cases with ADA2 deficiency. Rheumatol Int 2018; 38:
129-136.
Van Montfrans JM, Hartman EA, Braun KP, et al.
Phenotypic variability in patients with ADA2 deficiency
due to identical homozygous R169Q mutations.
Rheumatology (Oxford) 2016; 55: 902-910.
Caorsi R, Penco F, Grossi A, et al. ADA2 deficiency
(DADA2) as an unrecognised cause of early onset
polyarteritis nodosa and stroke: a multicentre national
study. Ann Rheum Dis 2017; 76: 1648-1656.
Kuriyama S, Kusaka Y, Fujimura M, et al. Prevalence
and clinicoepidemiological features of moyamoya disease
in Japan: findings from a nationwide epidemiological
survey. Stroke 2008; 39: 42-47.

International Journal of Stroke, 10(1)

47. Duan L, Bao XY, Yang WZ, et al. Moyamoya disease in
China: its clinical features and outcomes. Stroke 2012; 43:
56-60.
48. Ahn IM, Park DH, Hann HJ, Kim KH, Kim HJ and Ahn
HS. Incidence, prevalence, and survival of moyamoya
disease in Korea: a nationwide, population-based study.
Stroke 2014; 45: 1090-1095.
49. Chen PC, Yang SH, Chien KL, Tsai IJ and Kuo MF.
Epidemiology of moyamoya disease in Taiwan: a
nationwide population-based study. Stroke 2014; 45:
1258-1263.
50. Uchino K, Johnston SC, Becker KJ and Tirschwell DL.
Moyamoya disease in Washington State and California.
Neurology 2005; 65: 956-958.
51. Kuroda S and Houkin K. Moyamoya disease: current
concepts and future perspectives. Lancet Neurol 2008; 7:
1056-1066.
52. Smith KR, Leventer RJ, Mackay MT, et al. Identification
of a novel RNF213 variant in a family with heterogeneous
intracerebral vasculopathy. Int J Stroke 2014; 9: E26-E27.
53. Kamada F, Aoki Y, Narisawa A, et al. A genomewide association study identifies RNF213 as the first
Moyamoya disease gene. J Hum Genet 2011; 56: 34-40.
54. Liu W, Morito D, Takashima S, et al. Identification of
RNF213 as a susceptibility gene for moyamoya disease
and its possible role in vascular development. PloS One
2011; 6: e22542.
55. Sun XS, Wen J, Li JX, et al. The association between the
ring finger protein 213 (RNF213) polymorphisms and
moyamoya disease susceptibility: a meta-analysis based
on case-control studies. Mol Genet Genomics 2016; 291:
1193-1203.
56. Ma YG, Zhang Q, Yu LB and Zhao JZ. Role of ring
finger protein 213 in Moyamoya disease. Chin Med J
(Engl) 2016; 129: 2497-2501.
57. Cecchi AC, Guo D, Ren Z, et al. RNF213 rare variants in
an ethnically diverse population with Moyamoya disease.
Stroke 2014; 45: 3200-3207.
58. Miskinyte S, Butler MG, Herve D, et al. Loss of BRCC3
deubiquitinating enzyme leads to abnormal angiogenesis
and is associated with syndromic moyamoya. Am J Hum
Genet 2011; 88: 718-728.
59. Martin JJ, Hausser I, Lyrer P, et al. Familial cervical
artery dissections: clinical, morphologic, and genetic
studies. Stroke 2006; 37: 2924-2929.
60. Debette S, Goeggel Simonetti B, Schilling S, et al. Familial
occurrence and heritable connective tissue disorders in
cervical artery dissection. Neurology 2014; 83: 2023-2031.
61. Grond-Ginsbach C, Chen B, Krawczak M, et al. Genetic
imbalance in patients with cervical artery dissection.
Current Genom 2017; 18: 206-213.
62. Kenet G, Lutkhoff LK, Albisetti M, et al. Impact of
thrombophilia on risk of arterial ischemic stroke or
cerebral sinovenous thrombosis in neonates and children:
a systematic review and meta-analysis of observational
studies. Circulation 2010; 121: 1838-1847.
63. Haywood S, Liesner R, Pindora S and Ganesan V.
Thrombophilia and first arterial ischaemic stroke: a
systematic review. Arch Dis Child 2005; 90: 402-405.

WSO Russian Language

Table of Contents for the Digital Edition of WSO Russian Language